GSKure
Therapeutic Target for Treating Neurogenetic Disorders
Company Overview
Snapshot
Founded in January 2016 by Hagit Eldar- Finkelman, Ph.D., GSKure operates with 1–10 employees. The company is currently in the Pre-Funding stage. In February 2016, GSKure was part of the first class of neurotech startups to graduate from Brainnovations.
Business overview
GSKure is an IP-based company focused on developing innovative proprietary GSK-3 peptide inhibitor drug candidates. The company's Kure products are designed with a novel approach, targeting a unique region at the GSK-3 protein surface known as the substrate binding site. These substrate-competitive inhibitors (SCIs) offer improved selectivity and low toxicity compared to traditional ATP-competitive inhibitors, providing significant advantages for clinical practice. GSKure operates within the Health Tech & Life Sciences sector, specifically focusing on drug discovery and development for neurogenetic disorders like Alzheimer's disease and Amyotrophic Lateral Sclerosis (ALS), serving patients and pharma companies.
Strategic signal
In February 2016, GSKure graduated from the Brainnovations program as part of its first class of neurotech startups. This milestone signals early validation of GSKure's innovative approach to developing therapeutic targets for neurogenetic disorders, positioning the company within a cohort of promising ventures in the neurotechnology space.
Log in to access full profile ›Company Intelligence Q&A
- Who founded GSKure?
- GSKure was founded by Hagit Eldar- Finkelman, Ph.D.
- When was GSKure founded?
- GSKure was founded in January 2016.
- What is GSKure's primary focus?
- GSKure focuses on developing innovative proprietary GSK-3 peptide inhibitor drug candidates for treating neurogenetic disorders.
- What is the product stage of GSKure's offerings?
- GSKure's products, including Kure, are currently in the R&D stage, as indicated by the company's product stage information.
- What significant milestone did GSKure achieve in early 2016?
- In February 2016, GSKure was among the first class of neurotech startups to graduate from the Brainnovations program.